Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
1.210
-0.020 (-1.63%)
At close: Jul 10, 2026, 4:00 PM EDT
1.250
+0.040 (3.31%)
After-hours: Jul 10, 2026, 7:57 PM EDT
Actuate Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
A large phase II randomized trial of elraglusib in first-line metastatic pancreatic cancer showed a significant and durable overall survival benefit, with a favorable safety profile and improved quality of life. The drug's unique mechanism and combinability position it as a promising new platform for pancreatic and other GI cancers.